Brian WhiteJan 11, 2023Basilea - a year of significant achievementBasilea's preliminary 2022 revenue performance and portfolio update, released this morning, reflect a period of significant commercial...
Brian WhiteJan 9, 2023CHF20m Astellas milestoneThe importance of the anti-fungal Cresemba has grown in recent years as the company has re-focussed on growing and developing its...
Brian WhiteDec 23, 2022Basilea - Cresemba approved in Japan The antifungal Cresemba (isavuconazole) has long dominated Basilea's anti-infectives franchise and now represents the largest antifungal...
Andrew KeithNov 9, 2022Basilea - Sustainable profitability Basilea's recent pivot has financially and strategically altered the company's dynamics. Our research note analysis the prospects for the...
Brian WhiteNov 2, 2022Basilea - Another oncology programme partneredSince its refocus on the long-established and successful anti-infectives franchise, Basilea has successfully partnered or divested its...
Brian WhiteOct 24, 2022Basilea - Positive data at IDweekThe anti-fungal Cresemba has been an enduring and highly successful cornerstone of Basilea's long-established anti-infectives franchise....